Table 2.
Hotspot mutation counts among cancers only, by HPV type/group and cancer histology
| HPV, histology | Total | 1 HS mutation | ≥2 HS mutations | P | OR | 95%CI | |||
|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | ||||||
| HPV type/group | |||||||||
| HPV16 | 38 | 28 | 73.7% | 10 | 26.3% | ||||
| HPV18/45 | 10 | 2 | 20.0% | 8 | 80.0% | 5.6 × 10−3 | 11.20 | 2.03 | 61.89 |
| Histology | |||||||||
| SCC | 24 | 18 | 75.0% | 6 | 25.0% | ref | |||
| ADC | 22 | 11 | 50.0% | 11 | 50.0% | 0.08 | 3.00 | 0.86 | 10.43 |
| SCC | |||||||||
| HPV16 | 22 | 17 | 76.2% | 5 | 23.8% | ||||
| HPV18/45 | 1 | 0 | 0.0% | 1 | 100.0% | 1.00 | - | - | - |
| ADC | |||||||||
| HPV16 | 13 | 9 | 69.2% | 4 | 30.8% | ||||
| HPV18/45 | 9 | 2 | 22.2% | 7 | 77.8% | 0.04 | 7.88 | 1.11 | 56.12 |
SCC = squamous cell carcinoma, ADC = adenocarcinoma; HS = hotspot. P = logistic regression; OR = odds ratio; CI = confidence interval. Significant P values are bolded. Results shown in italics are based on small counts and should be interpreted with caution. OR, 95%CI, and P values were estimated using logistic regression; tests were two-sided.